Xeris Biopharma Holdings, Inc. (XERS)
Data as of , from SEC Form 4 filings.
See up to 3 months of XERS. The 7-day demo opens the 1M and 3M ranges and puts XERS on your watchlist.
Start 7-day demoLatest XERS insider trades
About Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
- CHICAGO, IL
- 435
- 2018
- XNAS
XERS Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 10 | 134,998 | $1.20M |
| Tax withholding / forfeiture | 2 | 58,563 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
XERS insider transactions (Form 4)
4949 Form 4 filings on record, the earliest from Nov 26, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Steven Pieper - Officer | Open-market sale | Common Stock | 5,000 | $9.41 footnote F2 | $47K | |
| ||||||
| Kevin McCulloch - Officer | Open-market sale | Common Stock | 15,000 | $9.41 footnote F2 | $141K | |
| ||||||
| Beth Hecht - Officer | Open-market sale | Common Stock | 16,666 | $9.41 footnote F2 | $157K | |
| ||||||
| Kevin McCulloch - Officer | Open-market sale | Common Stock | 25,000 | $10.00 | $250K | |
| Kevin McCulloch - Officer | Open-market sale | Common Stock | 15,000 | $8.49 footnote F2 | $127K | |
| ||||||
| Beth Hecht - Officer | Open-market sale | Common Stock | 16,666 | $8.49 footnote F2 | $141K | |
| ||||||
| Steven Pieper - Officer | Open-market sale | Common Stock | 5,000 | $8.50 | $43K | |
| John Patrick Shannon Jr. - Officer | Tax withholding / forfeiture | Common Stock | 36,645 footnote F1 | $8.08 | $296K | |
| ||||||
| Kevin McCulloch - Officer | Tax withholding / forfeiture | Common Stock | 21,918 footnote F1 | $8.08 | $177K | |
| ||||||
| Steven Pieper - Officer | Open-market sale | Common Stock | 5,000 | $8.50 | $43K | |
| Kevin McCulloch - Officer | Open-market sale | Common Stock | 15,000 | $8.02 footnote F2 | $120K | |
| ||||||
| Beth Hecht - Officer | Open-market sale | Common Stock | 16,666 | $8.01 footnote F2 | $134K | |
| ||||||
| Steven Pieper - Officer | Open-market sale | Common Stock | 17,400 | $8.50 | $148K | |
| Steven Pieper - Officer | Open-market sale | Common Stock | 27,600 | $8.52 footnote F3 | $235K | |
| ||||||
| Nerissa Kreher - Director | Grant or award | Common Stock | 33,582 footnote F1 | $0.00 | - | |
| Nerissa Kreher - Director | Grant or award | Stock Option (Right to Buy) | 37,910 | $8.00 | $303K | |
| ||||||
| Kevin McCulloch - Officer | Open-market sale | Common Stock | 90,000 | $8.03 footnote F2 | $723K | |
| ||||||
| Beth Hecht - Officer | Open-market sale | Common Stock | 16,666 | $8.03 footnote F2 | $134K | |
| ||||||
| Garheng Kong - Director | Grant or award | Common Stock | 24,193 footnote F1 | $0.00 | - | |
| Garheng Kong - Director | Grant or award | Stock Option (Right to Buy) | 32,996 | $6.15 | $203K | |
| ||||||
| Marla Persky - Director | Open-market sale | Common Stock | 15,500 | $5.90 footnote F2 | $91K | |
| Marla Persky - Director | Grant or award | Common Stock | 24,193 footnote F3 | $0.00 | - | |
| Marla Persky - Director | Grant or award | Stock Option (Right to Buy) | 32,996 | $6.15 | $203K | |
| ||||||
| Dawn Halkuff - Director | Open-market sale | Common Stock | 20,000 | $6.09 footnote F2 | $122K | |
| Dawn Halkuff - Director | Grant or award | Common Stock | 24,193 footnote F3 | $0.00 | - | |
| Dawn Halkuff - Director | Grant or award | Stock Option (Right to Buy) | 32,996 | $6.15 | $203K | |
| ||||||
| Barbara-Jean Anne Bormann-Kennedy - Director | Open-market sale | Common Stock | 16,000 | $6.09 footnote F2 | $98K | |
| Barbara-Jean Anne Bormann-Kennedy - Director | Grant or award | Common Stock | 24,193 footnote F3 | $0.00 | - | |
| Barbara-Jean Anne Bormann-Kennedy - Director | Grant or award | Stock Option (Right to Buy) | 32,996 | $6.15 | $203K | |
| ||||||
| John Johnson - Director | Open-market sale | Common Stock | 15,000 | $6.09 footnote F2 | $91K | |
| John Johnson - Director | Grant or award | Common Stock | 24,193 footnote F3 | $0.00 | - | |
| John Johnson - Director | Grant or award | Stock Option (Right to Buy) | 32,996 | $6.15 | $203K | |
| ||||||
| Grant or award | Common Stock | 24,193 footnote F1 | $0.00 | - | ||
| Grant or award | Stock Option (Right to Buy) | 32,996 | $6.15 | $203K | ||
| ||||||
| Beth Hecht - Officer | Open-market sale | Common Stock | 16,667 | $6.06 footnote F2 | $101K | |
| ||||||
| Beth Hecht - Officer | Open-market sale | Common Stock | 16,667 | $6.23 footnote F2 | $104K | |
| ||||||
| Beth Hecht - Officer | Open-market sale | Common Stock | 16,667 | $5.99 footnote F2 | $100K | |
| ||||||
| Open-market sale | Common Stock | 10,834 | $5.54 footnote F2 | $60K | ||
| ||||||
| Kevin McCulloch - Officer | Option exercise | Common Stock | 48,894 | $4.09 | $200K | |
| Kevin McCulloch - Officer | Option exercise | Common Stock | 4 | $3.94 | $16 | |
| Kevin McCulloch - Officer | Option exercise | Stock Option (Right to Buy) | 48,894 | $4.09 | $200K | |
| Kevin McCulloch - Officer | Option exercise | Stock Option (Right to Buy) | 4 | $3.94 | $16 | |
| Steven Pieper - Officer | Option exercise | Common Stock | 27,891 | $4.09 | $114K | |
| Steven Pieper - Officer | Option exercise | Common Stock | 14,036 | $5.93 | $83K | |
| Steven Pieper - Officer | Option exercise | Stock Option (Right to Buy) | 27,891 | $0.00 | - | |
| Steven Pieper - Officer | Option exercise | Stock Option (Right to Buy) | 14,036 | $0.00 | - | |
| Beth Hecht - Officer | Open-market sale | Common Stock | 16,567 | $6.24 footnote F2 | $103K | |
| Beth Hecht - Officer | Open-market sale | Common Stock | 100 | $7.06 | $706 | |
| ||||||
| Anh Tu Nguyen - Officer | Tax withholding / forfeiture | Common Stock | 29,300 footnote F1 | $6.88 | $202K | |
| ||||||
Recent XERS Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| BETH HECHT | Officer | 16,666 | $159K | View on EDGAR | |
| KEVIN MCCULLOCH | Officer | 70,000 |
XERS insider trading FAQ
What is the latest insider trade for XERS?
Xeris Biopharma Holdings, Inc. (XERS) had 12 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for XERS runs to 49 Form 4 filings, the earliest from 2024-11-26. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying XERS stock?
No insider purchases of XERS were filed in the last 90 days.
How many insiders are selling XERS stock?
10 insider sales of XERS were filed in the last 90 days, totaling $1.20M.
Where can I see XERS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects XERS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Steven Pieper view on EDGAR
- - Kevin McCulloch view on EDGAR
- - Beth Hecht view on EDGAR
- - Kevin McCulloch view on EDGAR
- - Kevin McCulloch view on EDGAR
- - Beth Hecht view on EDGAR
- - Steven Pieper view on EDGAR
- - John Patrick Shannon Jr. view on EDGAR
- - Kevin McCulloch view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where XERS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow XERS with a 7-day demo
- XERS on your watchlist
- Every XERS Form 4 filing on record
- Up to 3 months of XERS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive